Matches in SemOpenAlex for { <https://semopenalex.org/work/W4302425165> ?p ?o ?g. }
- W4302425165 endingPage "176" @default.
- W4302425165 startingPage "164" @default.
- W4302425165 abstract "Vismodegib, as an exogenous Indian hedgehog (Ihh) antagonist, has been approved by the Food and Drug Administration (FDA) for the clinical treatment of patients with basal cell carcinoma, and previous observations implicate the potential therapeutic of vismodegib in osteoarthritis treatment. However, there is no direct evidence for the role of Ihh signaling in intervertebral discs (IVDs) homeostasis of adult mice. The aim of the present study is to assess the effect of systemic administration of Smoothened inhibitor (SMOi) - vismodegib on IVDs homeostasis during the adult stage.The expression of glioma-associated oncogene homolog 1 (Gli1), the downstream targeting gene of Ihh signaling, in IVDs of adult mice after receiving systemic administration of SMOi was examined by immunohistochemistry. The pathological changes of vertebral bodies after SMOi treatment were evaluated by X-ray and micro-CT. The effects of SMOi on homeostasis of IVDs including cartilaginous endplates (CEP), growth plates (GP) and annulus fibrous (AF) were evaluated by histological analysis. The expressions of Aggrecan, Matrix metalloproteinase 13 (MMP13) and Runt-related transcription factor 2 (Runx2), in IVDs were also investigated by immunohistochemistry. Changes in chondrocyte apoptosis and proliferation in IVDs were evaluated by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay and analyzing the expression of the cell proliferation antigen Ki-67.Systemic administration of SMOi significantly decreased the expression of Gli1 in IVDs that indicating effective inhibition of Ihh signaling. Bone mass of vertebral bodies was diminished after SMOi treatment. Moreover, IVDs degeneration (IDD) like defects including CEP sclerosis, degenerative nucleus pulposus (NP) and fissure within AF, as well as narrowed or fused GP and loss bone mass of vertebral bodies was observed in SMOi-treated mice. The severity of IDD was time-dependent with the administration of SMOi treatment after 2-8 weeks. The expressions of Aggrecan, MMP13 and Runx2 in IVDs of mice receiving SMOi treatment were significantly decreased. In addition, chondrocyte apoptosis was significantly enhanced, while chondrocyte proliferation was significantly inhibited.Our study propose that systemic administration of vismodegib damages IVDs homeostasis via inhibition of Ihh signaling in adult mice. The clinical application of Ihh signaling antagonists such as vismodegib should be careful considering these side adverse.Vismodegib as an exogenous antagonist of Ihh signaling has been approved by the FDA for the clinical treatment of patients with basal cell carcinoma. However, it is still unknown whether vismodegib will has adverse effects on the patient or animal model of IVDs cartilage homeostasis. Based on our study, systemic administration of vismodegib damages IVDs homeostasis via inhibition of Ihh signaling in adult mice and special attention should be paid to the clinical application of vismodegib." @default.
- W4302425165 created "2022-10-06" @default.
- W4302425165 creator A5000677856 @default.
- W4302425165 creator A5008330805 @default.
- W4302425165 creator A5012587136 @default.
- W4302425165 creator A5050338926 @default.
- W4302425165 creator A5052046758 @default.
- W4302425165 creator A5060037355 @default.
- W4302425165 creator A5064523767 @default.
- W4302425165 creator A5064842058 @default.
- W4302425165 creator A5064973189 @default.
- W4302425165 creator A5067307300 @default.
- W4302425165 creator A5070778745 @default.
- W4302425165 creator A5074215346 @default.
- W4302425165 creator A5076871250 @default.
- W4302425165 creator A5078143614 @default.
- W4302425165 date "2022-09-01" @default.
- W4302425165 modified "2023-10-16" @default.
- W4302425165 title "Exogenous Indian hedgehog antagonist damages intervertebral discs homeostasis in adult mice" @default.
- W4302425165 cites W1533220576 @default.
- W4302425165 cites W1855766111 @default.
- W4302425165 cites W1969240589 @default.
- W4302425165 cites W1983023842 @default.
- W4302425165 cites W1987226609 @default.
- W4302425165 cites W1989465440 @default.
- W4302425165 cites W1993851741 @default.
- W4302425165 cites W1994737927 @default.
- W4302425165 cites W1998538991 @default.
- W4302425165 cites W2029500622 @default.
- W4302425165 cites W2030604088 @default.
- W4302425165 cites W2040184606 @default.
- W4302425165 cites W2043088793 @default.
- W4302425165 cites W2044687174 @default.
- W4302425165 cites W2060861339 @default.
- W4302425165 cites W2070184849 @default.
- W4302425165 cites W2086211715 @default.
- W4302425165 cites W2089233425 @default.
- W4302425165 cites W2110341920 @default.
- W4302425165 cites W2116099686 @default.
- W4302425165 cites W2132345567 @default.
- W4302425165 cites W2134355392 @default.
- W4302425165 cites W2140194336 @default.
- W4302425165 cites W2150666277 @default.
- W4302425165 cites W2159757693 @default.
- W4302425165 cites W2279072747 @default.
- W4302425165 cites W2297680570 @default.
- W4302425165 cites W2342486161 @default.
- W4302425165 cites W2416411461 @default.
- W4302425165 cites W2467796320 @default.
- W4302425165 cites W2752835339 @default.
- W4302425165 cites W2771225839 @default.
- W4302425165 cites W2794308260 @default.
- W4302425165 cites W2889964564 @default.
- W4302425165 cites W2890027764 @default.
- W4302425165 cites W2898486007 @default.
- W4302425165 cites W2908811895 @default.
- W4302425165 cites W2966899140 @default.
- W4302425165 cites W2971615603 @default.
- W4302425165 cites W3020875021 @default.
- W4302425165 cites W3048278095 @default.
- W4302425165 cites W3125740254 @default.
- W4302425165 cites W3164603003 @default.
- W4302425165 cites W3184297834 @default.
- W4302425165 cites W3200429793 @default.
- W4302425165 cites W4211136641 @default.
- W4302425165 cites W4293765706 @default.
- W4302425165 cites W4361868163 @default.
- W4302425165 cites W594600995 @default.
- W4302425165 cites W79815117 @default.
- W4302425165 doi "https://doi.org/10.1016/j.jot.2022.09.009" @default.
- W4302425165 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36263384" @default.
- W4302425165 hasPublicationYear "2022" @default.
- W4302425165 type Work @default.
- W4302425165 citedByCount "1" @default.
- W4302425165 countsByYear W43024251652023 @default.
- W4302425165 crossrefType "journal-article" @default.
- W4302425165 hasAuthorship W4302425165A5000677856 @default.
- W4302425165 hasAuthorship W4302425165A5008330805 @default.
- W4302425165 hasAuthorship W4302425165A5012587136 @default.
- W4302425165 hasAuthorship W4302425165A5050338926 @default.
- W4302425165 hasAuthorship W4302425165A5052046758 @default.
- W4302425165 hasAuthorship W4302425165A5060037355 @default.
- W4302425165 hasAuthorship W4302425165A5064523767 @default.
- W4302425165 hasAuthorship W4302425165A5064842058 @default.
- W4302425165 hasAuthorship W4302425165A5064973189 @default.
- W4302425165 hasAuthorship W4302425165A5067307300 @default.
- W4302425165 hasAuthorship W4302425165A5070778745 @default.
- W4302425165 hasAuthorship W4302425165A5074215346 @default.
- W4302425165 hasAuthorship W4302425165A5076871250 @default.
- W4302425165 hasAuthorship W4302425165A5078143614 @default.
- W4302425165 hasBestOaLocation W43024251651 @default.
- W4302425165 hasConcept C105702510 @default.
- W4302425165 hasConcept C126322002 @default.
- W4302425165 hasConcept C134018914 @default.
- W4302425165 hasConcept C142724271 @default.
- W4302425165 hasConcept C145837895 @default.
- W4302425165 hasConcept C196795494 @default.
- W4302425165 hasConcept C204232928 @default.